Clinical trial
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
NCT00039455 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00039455 |
|---|---|
| Title | Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase I Study of Herceptin/Flavopiridol in HER-2 Positive Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | trastuzumab, alvocidib, laboratory biomarker analysis, pharmacological study |
| Enrollment | 50 |
| Start date | Apr 1, 2002 |
| Primary completion | Dec 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: